US Oncology, Inc. Sustainability Profile
US Oncology, Inc., a prominent player in the oncology sector, is headquartered in the United States and operates extensively across various regions. Founded in 1998, the company has established itself as a leader in cancer care, focusing on innovative treatment solutions and comprehensive support services for patients and healthcare providers. Specialising in community-based cancer care, US Oncology offers a range of services, including clinical research, patient management, and advanced treatment options. Their unique approach integrates cutting-edge technology with a patient-centric philosophy, ensuring high-quality care tailored to individual needs. With a strong market position, US Oncology has achieved significant milestones, including partnerships with numerous healthcare facilities and a robust network of oncology practices. Their commitment to improving patient outcomes and advancing cancer treatment continues to set them apart in the industry.
DitchCarbon Score
How does US Oncology, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
US Oncology, Inc.'s score of 52 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
US Oncology, Inc., headquartered in the United States, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of McKesson Corporation, which may influence its climate commitments and reporting practices. As part of its corporate family, US Oncology, Inc. inherits climate initiatives and targets from McKesson Corporation. However, there are no documented reduction targets or specific climate pledges available for US Oncology, Inc. at this time. The lack of emissions data and reduction initiatives suggests that the company may still be in the process of establishing its own climate strategy or reporting framework. In the broader context, McKesson Corporation, as the parent company, may have its own sustainability goals and emissions reduction strategies that could impact US Oncology, Inc. in the future. As the industry increasingly focuses on climate action, it is likely that US Oncology, Inc. will align with these efforts to enhance its environmental performance.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 92,194,000 | 00,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 188,912,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 28,733,000 | 00,000,000 | 00,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 |
How Carbon Intensive is US Oncology, Inc.'s Industry?
How Carbon Intensive is US Oncology, Inc.'s Location?
US Oncology, Inc.'s Scope 3 Categories Breakdown
US Oncology, Inc.'s Scope 3 emissions, which increased by 12% last year and increased significantly since 2016, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 98% of Scope 3 emissions.
Top Scope 3 Categories
US Oncology, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
US Oncology, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
